Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

Eli Lilly has released detailed results from the Phase III QWINT-2 and QWINT-5 trial showing that its once weekly insulin efsitora (efsitora alfa) demonstrated a similar reduction in HbA1C levels ...

Insulin efsitora is a new basal insulin that can be given once weekly. New research findings comparing efsitora with degludec are summarized in a short video.

Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed ...

Medscape Medical News, September 12, 2024 EASD 2024 Once-Weekly Insulin Looks Good in T2D, but Risk Seen in T1D Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes ...

Medscape Medical News, September 12, 2024 EASD 2024 Once-Weekly Insulin Looks Good in T2D, but Risk Seen in T1D Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes ...

Eli Lilly is its nearest rival, developing a once-weekly rival, known as insulin efsitora, which has shown safety and efficacy in two of five ongoing phase 3 trials. Insulin icodec is an insulin ...

Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for ...